>

WEBINARS

RSS
>

MEETINGS / EVENTS

RSS

October 13 - 17 2012, 12:00 AM - 12:00 AM

ANESTHESIOLOGY 2012

>

FDA MEDWATCH ALERTS

RSS

May 16, 2012

Hydromorphone Hydrochloride Recall

Summary:

Hydromorphone Hydrochloride Recall

April 18, 2012

Morphine Sulfate Injection USP, 4 mg/mL (C-II), 1 mL fill in 2.5 mL Carpuject by Hospira, Inc: Recall - May Contain More Than Intended Fill Volume

Summary:

Customer report of two Carpujects syringes containing more than the 1 mL labeled fill volume. Opioid pain medications such as morphine have life-threatening consequences if overdosed. Those consequences can include respiratory depression (slowed breathing or suspension of breathing), and low blood pressure.

March 05, 2012

Cardiac Science Powerheart, CardioVive, CardioLife; GE Responder and Responder Pro; and Nihon-Kohden Automated External Defibrillators (AEDs): Class I Recall - Defective Component

Summary: FDA notified healthcare professionals and medical care organizations of the Class 1 recall of the listed AEDs which contain a component that may fail unexpectedly due to a defect. If the component were to fail during a rescue attempt, the AED may not deliver defibrillation therapy, causing serious adverse health consequences, including death. The unit’s self test may not detect the failure or impending failure of the component.

>

ASA FEATURED PRODUCT

Anesthesiology Continuing Education (ACE) Program

SKU: 30702-12CE

... Read more »

Single Copies, Member Price: $300

Update on Propofol Shortage and Importation of Fresenius Propoven 1% (propofol 1%)

Chicago — (March 16, 2010) 

 


FDA Authorizes APP to Resume Importation of Fresenius Propoven 1% (propofol 1%) to Alleviate Ongoing Shortage of Propofol Injection in the United States

Due to the ongoing critical shortage of Propofol Injection in the United States, and in conjunction with the FDA, APP has been authorized to reintroduce Fresenius Propoven 1% (propofol 1%) to the US market. APP will also continue to offer DIPRIVAN® (propofol 1%) and increase supply of APP Propofol 1% (authorized generic DIPRIVAN).

FDA previously granted APP approval to import and distribute Fresenius Propoven 1% (propofol 1%) to help alleviate shortages following two voluntary recalls from other manufacturers of propofol injection. This temporary importation ended on February 1, 2010 and has now been reinstated to alleviate the ongoing shortage following continued supply issues from other manufacturers. APP has indicated that it is committed to providing the US market with available quantities of Fresenius Propoven 1% (propofol 1%), DIPRIVAN® (propofol 1%) and APP Propofol 1% (authorized generic DIPRIVAN®) and anticipates Fresenius Propoven (propofol 1%) will be used to address the shortage until the marketplace stabilizes. Fresenius Propoven 1% (propofol 1%) is manufactured by APP’s parent company Fresenius Kabi AG, in FDA compliant facilities.

Please see the following “Dear Healthcare Professional” letter or the FDA’s website for more information.

http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050792.htm#propofol.

THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS

Anesthesiologists: Physicians providing the lifeline of modern medicine. Founded in 1905, the American Society of Anesthesiologists is an educational, research and scientific association with 46,000 members organized to raise and maintain the standards of the medical practice of anesthesiology and improve the care of the patient.

For more information on the field of anesthesiology, visit the American Society of Anesthesiologists Web site at www.asahq.org. For patient information, visit LifeLineToModernMedicine.com

###

Contact:

American Society of Anesthesiologists
communications@asahq.org
847-825-5586